BioSpace News Archive

Revolo Biotherapeutics today announced topline data from its allergen challenge mapping study evaluating the immunologic mechanisms, safety, and tolerability of the Company’s immune-resetting drug, ‘1104, in atopic adults with moderate to severe allergy.

Rhythm Pharmaceuticals, Inc. today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 7, 2023 to report its third quarter 2023 financial results and provide a corporate update.

Health Catalyst, Inc. will release its third quarter 2023 operating results on Wednesday, November 8, 2023, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T. on the same day.

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company) today announced that interim data from the Phase 1/2 AEROW clinical trial of aerosolized 4D-710 for treatment of cystic fibrosis lung disease will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) and that it will host a live webcast to discuss the data in detail and provide a program update on Wednesday, November 1, 2023 at 4:30 p.m. ET.

Adial Pharmaceuticals, Inc. recently hosted a virtual key opinion leader webinar with addiction experts Joseph Volpicelli, M.D., Ph.D., Executive Director and Founder of the Volpicelli Center; and Jonathan Hunt-Glassman, MBA, Chief Executive Officer and Co-founder of Oar Health, to discuss alcohol use disorder, the current treatment landscape, and the need for non-abstinence-based therapeutics.

Immutep Limited, is pleased to announce that it has received a A$1,134,882 cash rebate from the Australian Federal Government’s R&D tax incentive program.

Flashpoint Therapeutics announced today a $10M seed financing round led by Beta Lab.

Ventric Health today announced that its medical device, the Vivio System™, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Be Biopharma, Inc. will present research from preclinical studies during the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Meeting. In an oral presentation on Friday, October 27, from 11:00 to 13:00 CEST.

ImmunoPrecise Antibodies Ltd. announces that its subsidiary, BioStrand®, has commercially launched its state-of-the-art Retrieval Augmented Generation -based Large Language Model platform.